Skeletal Ewing's sarcoma was associated with similar overall survival compared to extra-skeletal Ewing's sarcoma (64% vs 61%; p=0.85), indicating outcomes are not determined by the site of origin.
Cohort (n=300)
Yes
Does extra-skeletal origin compared to skeletal origin affect overall survival in patients with Ewing's sarcoma?
Oncological outcomes of Ewing's sarcoma are related to tumour characteristics and patient age, not whether they arise in bone or soft tissue.
Absolute Event Rate: 64% vs 61%
p-value: p=0.85
The aim of this study was to identify whether there was any difference in patient, tumour, treatment or outcome characteristics between patients with skeletal or extra-skeletal Ewing's sarcoma. We identified 300 patients with new primary Ewing's sarcoma diagnosed between 1980 and 2005 from the centres' local database. There were 253 (84%) with skeletal and 47 (16%) with extra-skeletal Ewing's sarcomas. Although patients with skeletal Ewing's were younger (mean age 16.8 years) than those with extra-skeletal Ewing's sarcoma (mean age 27.5 years), there was little difference between the groups in terms of tumour stage or treatment. Nearly all the patients were treated with chemotherapy and most had surgery. There was no difference in the overall survival of patients with skeletal (64%) and extra-skeletal Ewing's sarcoma (61%) (p = 0.85), and this was also the case when both groups were split by whether they had metastases or not. This large series has shown that the oncological outcomes of Ewing's sarcoma are related to tumour characteristics and patient age, and not determined by whether they arise in bone or soft tissue.
Pradhan et al. (Fri,) conducted a cohort in Ewing's sarcoma (n=300). Skeletal Ewing's sarcoma vs. Extra-skeletal Ewing's sarcoma was evaluated on Overall survival (p=0.85). Skeletal Ewing's sarcoma was associated with similar overall survival compared to extra-skeletal Ewing's sarcoma (64% vs 61%; p=0.85), indicating outcomes are not determined by the site of origin.